MedWatch - The FDA Safety Information and Adverse Event Reporting Program

Bristol-Myers Squibb notified healthcare professionals of medication errors

due to name confusion between Serzone, indicated for the treatment of

depression, and Seroquel, a product of AstraZeneca, indicated for the

treatment of schizophrenia. The overlapping strengths (100 mg and 200 mg),

the dosage form (tablets), the dosing interval (BID), and the fact that

these two products are stocked close together in pharmacies were critical in